Phaseline

Targets › HMG1

HMG1 (High mobility group protein B1): drug programs, companies and trials

1 program from 1 company in 4 trials: 2 Phase 3, 2 Phase 1; Genitourinary, Infectious disease, Other; next expected readout Mar 2027.

Multifunctional redox sensitive protein with various roles in different cellular compartments. In the nucleus is one of the major chromatin-associated non-histone proteins and acts as a DNA chaperone involved in replication, transcription, chromatin remodeling, V(D)J recombination, DNA repair and genome stability. (UniProt, P09429)

Open in Phaseline: the race on HMG1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Basilea Pharmaceuticafosmanogepix
GPI-anchored wall transfer protein 1 inhibitor
IPCS1, HMG1, FKS1Phase 3Candidemia; Invasive Mold Infections; Healthy Adult Participants; End Stage Renal Disease on DialysisMar 2027

Conditions

Candidemia (1) Invasive Mold Infections (1) Healthy Adult Participants (1) End Stage Renal Disease on Dialysis (1)

Modalities

small molecule (1)

Companies

Basilea Pharmaceutica (1)

Related targets

IPCS1 (1) FKS1 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.